Marpai Earnings Call Transcripts
Fiscal Year 2025
-
Q3 2025 saw a 42% revenue decline but improved operating efficiency and reduced losses. New client wins, a $3.9M capital raise, and technology upgrades position the company for growth in a rapidly expanding TPA market.
-
Q2 2025 saw a 35% revenue decline but significant improvements in operating expenses and net loss, reflecting strategic exits from unprofitable contracts. The relaunch of MarpaiRx and ongoing cost reductions position the company for profitability in Q1 2026.
-
Q1 2025 saw a 27% revenue decline but significant improvements in operating loss and net loss, driven by cost reductions and a focus on higher-margin clients. Leadership changes and a strong pipeline support expectations for profitability and cash flow positivity by year-end.
Fiscal Year 2024
-
Losses were sharply reduced in 2024 through cost controls and strategic client focus, with adjusted EBITDA loss improving year-over-year. New PBM services and partnerships are expected to drive growth and profitability in 2025.
-
Leadership highlighted operational efficiencies, reduced expenses, and improved operating loss, while securing new clients and investments. A robust sales pipeline and industry tailwinds position the company for growth in 2025.
-
Revenue fell 28% year-over-year, but cash operating expenses dropped 38%, and net cash increased by $600,000 in Q2 2024. Leadership remains committed to profitable growth and positive cash flow, with a $22 billion addressable market opportunity.